Welcome to our dedicated page for Lexaria Bioscience SEC filings (Ticker: LEXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexaria Bioscience Corp. filings document a Nevada biotechnology company developing and licensing DehydraTECH, its oral drug delivery platform. Registration statements and periodic disclosure materials describe the company's intellectual property licensing segment, research and development activities, B2B initiatives, common stock, warrants, stock options, and risk factors tied to its technology and commercialization model.
Lexaria's 8-K filings record material financing and capital-structure events, including securities purchase agreements, registered direct offerings, concurrent private placement warrants, and the termination of an at-the-market sales agreement. Other filings cover annual meeting voting results, auditor appointment, Nasdaq listing-compliance notices for common stock, and Form 25 records involving warrant listing and registration status.
Lexaria Bioscience Corp. reported a net loss attributable to shareholders of $5.0 million for the nine months ended May 31, 2026, improved from $9.2 million a year earlier, driven mainly by lower research and development spending after completion of a prior Phase 1b trial. Revenue fell sharply to $20,000 from $531,923, reflecting expiry of a key licensing contract and reduced B2B activity as the company pivots toward pharmaceuticals.
Cash was $3.5 million with current liabilities of $0.4 million, yielding working capital of $3.7 million, supported by $6.5 million in net equity proceeds from two registered direct offerings. Management nonetheless states there is substantial doubt about the ability to continue as a going concern beyond the first quarter of fiscal 2027 without additional financing or partnerships.
The company continues to develop its DehydraTECH drug delivery platform, focusing on GLP‑1, GIP and glucagon drugs for diabetes and weight loss, and CBD for hypertension under an active FDA IND. It is running new human and animal GLP‑1 studies and exploring strategic options under an extended material transfer agreement with a pharmaceutical counterparty. Lexaria also discloses it received a Nasdaq notice for failing the $1.00 minimum bid price requirement and may need corporate actions, such as a reverse split, to maintain its listing.
Lexaria Bioscience Corp. reports lower revenue and a narrower loss while highlighting going concern risks. For the six months ended February 28, 2026, revenue fell to $20,000 from $357,923, reflecting the expiration of a key licensing contract and reduced B2B focus. Net loss attributable to shareholders improved to $3.0 million from $5.4 million as research and development spending decreased after completing a major GLP‑1 clinical trial.
Cash rose to $5.1 million with working capital of $5.6 million, largely driven by two equity financings that raised about $6.5 million in net proceeds. Despite this, accumulated deficit reached $66.5 million, and recurring losses and negative cash flows led management to state there is “substantial doubt” about the company’s ability to continue as a going concern over the next year. Management expects current cash to fund operations only through the first quarter of fiscal 2027 and plans to rely on additional equity or partnership funding.
Lexaria Bioscience Corp. director Christopher Bunka reported a bona fide gift of 100,000 common shares back to Lexaria, which were returned to the company’s treasury. This was not an open‑market sale and carried no stated share price.
After the gift, Bunka holds 273,543 common shares directly and 281,912 common shares indirectly through a private holding company as of the reported date. He also retains multiple stock option awards over additional common shares, with exercise prices between 1.0400 and 3.0000 per share and expirations from 2026 through 2030.
Lexaria Bioscience Corp. reported that on February 4, 2026 it received a Nasdaq notice that its common stock no longer meets the Nasdaq Capital Market’s minimum bid price requirement of $1.00 per share. The stock remains listed and continues to trade under the symbol LEXX.
The company has 180 calendar days, until August 3, 2026, for its closing bid price to be at or above $1.00 per share for at least 10 consecutive business days (and up to 20 at Nasdaq’s discretion) to regain compliance. If it does not do so, Lexaria may qualify for an additional 180‑day period if it meets all other initial listing standards and notifies Nasdaq of plans to cure the deficiency, potentially including a reverse stock split.
If Lexaria cannot meet these conditions, Nasdaq may move to delist the stock, and the company would then have the opportunity to appeal. Lexaria states that it intends to actively monitor its share price and evaluate options to address the deficiency, but it notes there is no assurance it will regain or maintain compliance.
Lexaria Bioscience Corp. reported the results of its annual shareholder meeting held on January 27, 2026. A total of 8,380,389 shares, or 37.71% of issued share capital as of December 1, 2025, were represented in person or by proxy.
Shareholders elected all seven director nominees, with approval levels ranging from 73.6% to 96.4%. They also approved the appointment of Malone Bailey LLP as auditors, with 97.0% of votes cast in favor.
In addition, shareholders voted to ratify the lawful actions of the directors for the past year, with 90.0% approval, signaling broad support for the company’s current leadership and governance decisions.
Lexaria Bioscience Corp. is registering up to 2,754,756 shares of common stock for resale by existing investors. These shares are issuable upon the exercise of outstanding warrants from a December 2025 private placement and related placement agent compensation. The company will not receive any money from stockholders’ resale of these shares.
If the warrants are exercised for cash, Lexaria would receive approximately $3.3 million in gross proceeds, which it plans to use for research and development, working capital and general corporate purposes. The company had 24,887,446 shares outstanding as of December 26, 2025, and its stock trades on the Nasdaq Capital Market under the symbol “LEXX”, with a last reported price of $0.809 per share on January 13, 2026.
Lexaria Bioscience Corp. has had its warrant class removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq filed a Form 25 notification stating that, under Section 12(b) of the Securities Exchange Act of 1934 and related rules, it has complied with its procedures to strike this warrant from listing and registration. The filing identifies only the company’s warrant as the affected class of securities and is signed on behalf of Nasdaq by an authorized officer.
Lexaria Bioscience Corp. reported a net loss of $1.6M for the quarter ended November 30, 2025, narrowing from $2.7M a year earlier as research and development spending declined to $671K from $2.0M. Quarterly revenue was $0, compared with $183,923 in the prior-year period, reflecting expiration of a key license and a strategic shift away from B2B product sales toward pharmaceutical applications of its DehydraTECH drug-delivery technology.
Cash rose to $4.3M from $1.8M at August 31, 2025, helped by $3.4M in net proceeds from a registered direct equity offering in September, leading to working capital of $3.9M. The company still had an accumulated deficit of $65.1M and disclosed that recurring losses and negative cash flows create substantial doubt about its ability to continue as a going concern, despite management’s expectation that current cash could fund operations into the first quarter of fiscal 2027. Subsequent to quarter-end, Lexaria raised an additional $3.0M net in a December registered direct offering with attached warrants.
Lexaria Bioscience Corp. entered a securities purchase agreement with institutional investors and completed a combined registered direct offering and private placement, issuing 2,661,600 shares of common stock at $1.315 per share and 2,661,600 warrants with a $1.19 exercise price for gross proceeds of approximately $3.5 million before fees.
The shares were sold under an effective shelf registration, while the warrants and their underlying shares were issued in a private placement under Securities Act exemptions, with a 4.99% beneficial ownership cap that can be increased to up to 9.99% on notice. Lexaria agreed to file a resale registration statement for the warrant shares within specified deadlines, accepted a 30-day restriction on additional equity issuance and new registration filings (subject to exceptions), and plans to use net proceeds for working capital and other general corporate purposes. H.C. Wainwright & Co. acted as placement agent, earning a 7.0% cash fee, 93,156 warrants with a $1.6438 exercise price, and specified expense reimbursements.
Lexaria Bioscience Corp. is offering 2,661,600 shares of common stock at $1.315 per share in a primary registered direct sale to institutional investors. Gross proceeds are expected to be $3,500,004.00, with net proceeds of about $3.0 million after placement fees and expenses, which the company plans to use to advance research and development, fund working capital and for other general corporate purposes.
Alongside the stock sale, Lexaria is issuing in a separate private placement warrants to purchase up to 2,661,600 additional shares at an exercise price of $1.19 per share. If all of these private placement warrants are exercised for cash, the company would receive roughly $3.1 million in additional net proceeds.
Shares outstanding were 22,225,846 as of December 14, 2025 and are expected to become 24,887,446 after this offering, excluding any warrant or option exercises. Based on a pro forma as adjusted net tangible book value of $0.35 per share as of August 31, 2025, investors buying in this offering face immediate dilution of $0.97 per share, and the company highlights risks related to stock price volatility, Nasdaq listing compliance and potential future dilution.